Stock Analysis
Data Source: SEC EDGAR 13F
Updated Hourly

Corvus Pharmaceuticals Inc (CRVS)

164 + Investors. Track Smart Money conviction in CRVS. See who's accumulating, reducing, or initiating positions.

Current Price
-- USD
Analyst Target
-- (0 analysts)
Upside
0.00%
Net Flow Q/Q
↑ +39
Streak
4Q ▲
Buyers last Q
68%

Smart Money Signals — CRVS

Based on 164 hedge funds · latest filing: 2026 Q1 · updated quarterly

📈

Buying streak — 4 quarters in a row

last 6Q
For 4 consecutive quarters, more hedge funds added CRVS than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.
🏔️

At the ownership peak (100% of max)

100% of all-time peak
164 hedge funds hold CRVS right now — the highest count in 3.0 years. When ownership is this concentrated, any bad news can trigger a chain reaction: one big fund sells, others follow. This is a classic 'crowded trade' — high popularity doesn't equal safety.
🚀

Fast accumulation — +80% more funds vs a year ago

fund count last 6Q
+73 new funds entered over the past year (+80% YoY). That's a rapid rush of institutional money. Fast accumulation often signals a major thesis — but it also means the stock could fall quickly if that thesis breaks.
🟢

More buyers than sellers — 68% buying

123 buying57 selling
Last quarter: 123 funds were net buyers (65 opened a brand new position + 58 added to an existing one). Only 57 were sellers (31 trimmed + 26 sold completely). A clear majority buying is a strong confirmation signal.
📈

More new buyers each quarter (+34 vs last Q)

new funds entering per quarter
Funds opening a new CRVS position: 31 → 24 → 31 → 65. A growing influx of new institutional buyers means the asset is still gathering momentum — the consensus hasn't fully saturated yet.
📌

Mixed — 31% long-term, 47% new

■ 31% conviction (2yr+) ■ 22% medium ■ 47% new
Of the 164 current holders: 51 (31%) held >2 years, 36 held 1–2 years, and 77 entered in the last year. A mixed base — the stock has long-term believers but also recent buyers who haven't been tested by a downturn yet.
💰

Value +172% but shares only +50% — price-driven

Value
+172%
Shares
+49%
Last quarter: the total dollar value of institutional holdings rose +172%, but actual share count only changed +50%. The gap is explained by the stock's price rising — not new buying. Strong value growth with weak share growth means the rally is price momentum, not fresh institutional demand.
🚀

Acceleration phase — new buyers rushing in

15 → 31 → 24 → 31 → 65 new funds/Q
New funds entering each quarter: 31 → 24 → 31 → 65. The pace of institutional discovery is accelerating sharply. This is the 'hot idea' phase — the thesis is being passed from fund to fund. You are not late — the accumulation wave is still building.
🏛️

Veteran-anchored — 42% veterans vs 49% newcomers

■ 42% veterans ■ 9% 1-2yr ■ 49% new
Entry-cohort mix of 172 holders: 72 (42%) are 2+ year veterans, 15 entered 1–2 years ago, and 85 (49%) joined within the past year. A veteran-weighted cap table skews toward institutional memory over fresh momentum.
✅

Strong quality — 23% AUM from major funds

23% from top-100 AUM funds
35 of 163 holders rank in the top 100 by AUM, accounting for 23% of total institutional value held. A meaningful share of the ownership value comes from the most well-resourced institutions.
5.2
out of 10
Moderate Exit Risk
Exit risk score 5.2/10 — some crowding factors present, but no critical concentration. Watch ownership trend over the next 1–2 quarters for direction.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Institutional Sentiment Summary — CRVS

In 2026 Q1, 123 hedge funds were net buyers of CRVS (65 opened a new position, 58 added to an existing one), while 57 reduced or exited (31 trimmed, 26 sold completely) — a 68% buyer ratio, indicating clear institutional accumulation. This marks 4 consecutive quarters of net institutional buying — a persistent conviction signal. 23% of total institutional value in CRVS is held by top-100 AUM funds, reflecting strong institutional quality. Net fund flow last quarter: +39 funds (more new holders than closures). Total institutional holders: 164.

Hedge Fund Ownership: CRVS

How many hedge funds hold CRVS — quarterly history vs. share price
Quarterly hedge fund ownership of CRVS vs. share price

Market Analysis: CRVS

Analyst Price Targets

Avg. Price Target
--

Analyst Recommendations

Stock Performance

Real-time

Company Profile: CRVS

-- --

Institutional ownership data sourced from SEC EDGAR Form 13F-HR filings.

Is It Too Late to Buy Corvus Pharmaceuticals Inc (CRVS) Based on Hedge Fund 13F Filings?

Signal Freshness measures how much CRVS has moved relative to its sector benchmark (XLV) since the 2026 Q1 13F filing. A stock that has barely outrun its sector is still a relatively fresh entry point — the fund's thesis has not yet been priced in by the broader market.

Since Quarter End March 31, 2026 · 79d ago
CRVS
-18.0%
XLV
+2.1%

CRVS outperformed XLV by -20.1% since March 31, 2026.

Since 13F Filing Date May 15, 2026 · 34d ago
CRVS
-2.5%
XLV
+3.2%

Since the filing became public, CRVS outperformed XLV by -5.7% .

Interpretation: The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference. Learn more →

Smart Money Signal ?
Limited Smart Money Interest

No strong consensus or elite conviction detected among institutional holders.

19 top-rated funds 4 high-conviction
Consensus
5.6
/ 10
breadth
×
Elite
4.0
/ 10
conviction
Hedge Fund Positioning: CRVS
164 + Investors

Track Smart Money conviction in CRVS. See who's accumulating, reducing, or initiating positions.

Metric All 13F Filers (2026 Q1) Prior (2025 Q4) Change
Funds Holding 164 125 31.2%
13F Shares 72M 48M 49.73%
Total Value $1.00B $368M 172.2%
New Positions 65 31 +34
Increased Positions 56 42 +14
Closed Positions 26 10 +16
Reduced Positions 30 29 +1
Total Calls 6 4 50.0%
Total Puts 3 5 -40.0%
PUT/CALL Ratio 0.5 1.25 Bullish

Statistics: CRVS

View More

Valuation Measures Data as of: --

Market Cap --
Enterprise Value --
Trailing P/E --
Forward P/E --
PEG Ratio (5yr expected) --
Price/Sales (ttm) --
Price/Book (mrq) --
Enterprise Value/Revenue --
Enterprise Value/EBITDA --
Beta (5Y Monthly) --
Short Ratio (Days to Cover) --
Short % of Float --

Financial Highlights

Profitability
Profit Margin --
Return on Assets (ttm) --
Return on Equity (ttm) --
Income Statement & Cash Flow
Revenue (ttm) --
Net Income Avi to Common (ttm) --
Diluted EPS (ttm) --
Total Cash (mrq) --
Total Debt/Equity (mrq) --
Levered Free Cash Flow (ttm) --

Institutional Holders (2026 Q1)

164 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in CRVS. Verified SEC 13F-HR filings.

QUARTER:
Top 25 CRVS holders by conviction (% of portfolio weight) — 2026 Q1 · Source: SEC Form 13F
# Investor % of Portfolio Shares Mkt Value
1 Adams Street Partners LLC 18.41% 3,275,616 $47.9M
2 Foresite Capital Management VI LLC 5.82% 1,831,233 $26.8M
3 Vivo Capital, LLC 3.43% 2,805,816 $41.0M
4 Catalio Capital Management, LP 2.73% 891,933 $13.0M
5 DCF Advisers, LLC 2.49% 637,500 $9.3M
6 Blue Owl Capital Holdings LP 2.14% 545,000 $8.0M
7 Boxer Capital Management, LLC 2.11% 1,100,000 $16.1M
8 Orbimed Advisors LLC 2.08% 7,165,006 $104.8M
9 Commodore Capital LP 1.91% 2,258,735 $33.0M
10 MPM BioImpact LLC 1.89% 1,674,875 $24.5M
11 Braidwell LP 0.86% 1,752,798 $25.6M
12 Spruce Street Capital LP 0.81% 231,585 $3.4M
13 Propel Bio Management, LLC 0.79% 85,791 $1.3M
14 Towerview LLC 0.66% 70,000 $1.0M
15 Perceptive Advisors LLC 0.66% 2,292,441 $33.5M
16 Diadema Partners LP 0.61% 244,811 $3.6M
17 Deep Track Capital, LP 0.60% 2,491,539 $36.5M
18 Sphera Funds Management LTD. 0.58% 247,961 $3.6M
19 Nextech Invest, Ltd. 0.46% 450,000 $6.6M
20 Avidity Partners Management LP 0.40% 115,000 $1.7M
21 Seven Fleet Capital Management LP 0.38% 82,890 $1.2M
22 Persistent Asset Partners Ltd 0.34% 62,051 $908K
23 Logos Global Management LP 0.33% 450,000 $6.6M
24 Emerald Mutual Fund Advisers Trust 0.33% 459,253 $6.7M
25 Emerald Advisers, LLC 0.32% 686,216 $10.0M
Investor Ownership
History 		% of Portfolio Prev % Rank Conviction Avg Buy Price 13F Score™ 3Y / 7Y Sell Timing Shares Mkt Value Change Change % Source Quarter Filed

Frequently Asked Questions — Corvus Pharmaceuticals Inc (CRVS)

What does the Smart Money Trend signal show for CRVS?

Buying streak — 4 quarters in a row: For 4 consecutive quarters, more hedge funds added CRVS than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

What is the institutional breadth score for CRVS?

More buyers than sellers — 68% buying: Last quarter: 123 funds were net buyers (65 opened a brand new position + 58 added to an existing one). Only 57 were sellers (31 trimmed + 26 sold completely). A clear majority buying is a strong confirmation signal.

What is the fund quality score for CRVS holders?

Strong quality — 23% AUM from major funds: 35 of 163 holders rank in the top 100 by AUM, accounting for 23% of total institutional value held. A meaningful share of the ownership value comes from the most well-resourced institutions.

How long have hedge funds held CRVS?

Mixed — 31% long-term, 47% new: Of the 164 current holders: 51 (31%) held >2 years, 36 held 1–2 years, and 77 entered in the last year. A mixed base — the stock has long-term believers but also recent buyers who haven't been tested by a downturn yet.

Is it too late to buy Corvus Pharmaceuticals Inc (CRVS) following the 2026 Q1 hedge fund 13F filings?

As of today, CRVS has moved -2.5% since the 2026 Q1 13F filing date (May 15, 2026), compared to +3.2% for the XLV sector ETF — an outperformance of -5.7%. Since the quarter end (March 31, 2026), CRVS has gained -18.0% vs +2.1% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Disclaimer: The information on this page is for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Institutional holdings data is sourced from SEC Form 13F filings and reflects positions as of the filing date. Past performance of any fund or portfolio is not indicative of future results. 13Foresight is not a registered investment adviser. Always conduct your own due diligence before making investment decisions.

Full history →